Hormone Therapy for Women in Jacksonville: A 2026 Guide

Medically reviewed by Jason Jacobson, APRN

For more than twenty years, a woman in Jacksonville asking her doctor about hormone therapy for hot flashes was likely to hear a version of the same answer: the risks are serious, the label carries the FDA’s strongest warning, and it is generally better to manage symptoms another way.

In November 2025 that changed, and the change was substantial enough that it is worth understanding whether you were turned down years ago or are considering this for the first time.

What the FDA did

On November 10, 2025, the FDA and HHS announced they would remove the boxed warning from more than twenty estrogen-containing hormone therapy products, including pills, patches and creams.

Specifically, the warnings removed relate to cardiovascular disease, breast cancer and probable dementia. Labels are being rewritten with age-specific guidance indicating that women may see long-term health benefits when hormone therapy is started within ten years of the onset of menopause.

One warning was not removed. The FDA is not removing the endometrial cancer warning for systemic estrogen-alone products. That risk is why women with a uterus are generally prescribed a progestogen alongside estrogen.

The agency also approved two new options at the same time: a generic version of conjugated estrogens, the first such approval in over thirty years, and a non-hormonal treatment for moderate to severe hot flashes.

Why the warning existed, and why it changed

The boxed warning traced back to the Women’s Health Initiative, a study of more than 26,000 women published in 2002 that linked hormone pills to higher rates of stroke, blood clots and breast cancer. Prescriptions fell sharply across every age group afterward, including among women in their early fifties.

Subsequent reanalysis produced a more age-dependent picture. An analysis of the original data found that women in their fifties taking estrogen-based therapy faced no increased risk of heart problems, while women in their seventies did. Data for women in their sixties was less clear, and the authors advised caution there.

That distinction, between starting therapy near the onset of menopause versus starting it decades later, is the basis for the new age-specific labeling.

The honest counterpoint

This deserves saying, because most clinic marketing about the change leaves it out.

Not all clinicians think the FDA got the scope right. Several have noted that removing the warning from vaginal estrogen was widely expected, since low-dose vaginal formulations have very little systemic absorption, but removing it from every systemic formulation surprised many specialists. The concern is that a blanket removal may signal to all menopausal women that systemic hormone therapy is appropriate for them, when it is not.

Hormone therapy remains FDA-approved for specific indications: moderate to severe hot flashes and night sweats, genitourinary symptoms, and prevention of osteoporosis in women at risk. For other uses, the evidence is less conclusive.

A useful way to hold both facts at once: the risks were overstated for a large group of women who were denied effective treatment, and hormone therapy is still a real medication with real contraindications rather than a wellness supplement.

Want a personalized answer rather than a general one? Call Slym Wellness at 904-788-3747 or book a consult. In-person visits in Jacksonville, virtual visits throughout Florida.

Symptoms worth treating

Perimenopause typically begins in the forties and can last several years before periods stop entirely. Common symptoms:

• Hot flashes and night sweats
• Sleep disruption, often waking at 3am
• Irregular or changing periods
• Mood changes, anxiety, irritability
• Brain fog and word-finding difficulty
• Vaginal dryness, painful sex, recurrent UTIs
• Joint aches
• Weight redistribution toward the midsection
• Reduced libido

Two things women in Jacksonville tell us repeatedly. First, that the symptoms started earlier than they expected and nobody told them perimenopause could begin in the early forties. Second, that they were told their labs were normal and sent home, which is frustrating and also somewhat expected, since hormone levels fluctuate dramatically during perimenopause and a single draw often does not capture it. Perimenopause is largely a clinical diagnosis based on age and symptoms, not a lab value.

Treatment options

Systemic estrogen, available as pills, patches, gels and sprays. Patches and gels avoid first-pass liver metabolism, which matters for some women’s risk profile.

Progestogen, prescribed alongside estrogen for any woman with a uterus, to protect the endometrium.

Low-dose vaginal estrogen, for vaginal dryness, painful sex and recurrent UTIs. Systemic absorption is very low, which is why specialists generally regard it as the safest formulation and why its warning removal was uncontroversial.

Non-hormonal options, including a newer FDA-approved treatment for moderate to severe hot flashes, for women who cannot or prefer not to use hormones.

On the term “bioidentical”: FDA-approved hormone therapy products include bioidentical forms of estradiol and progesterone. That is different from custom-compounded bioidentical preparations, which are not FDA-approved and not subject to the same testing. If a clinic markets compounded bioidenticals as inherently safer, ask what that claim is based on.

Who needs a careful conversation first

Hormone therapy is not appropriate for everyone. Discuss your full history with a provider, particularly any history of heart attack or stroke, blood clots in the legs or lungs, hormone-sensitive cancer, active liver disease, or unexplained vaginal bleeding. Your personal and family breast cancer and cardiovascular risk factors matter to the decision.

Timing matters too. The evidence supporting benefit is strongest for women starting within roughly ten years of menopause onset or before age 60.

Getting started in Jacksonville

Slym Wellness sees women in person at our Jacksonville office and virtually across Florida, serving Riverside, San Marco, Mandarin, Southside, Nocatee, St. Johns, Orange Park, Fleming Island, Jacksonville Beach, Ponte Vedra and Fernandina Beach.

This article is general information, not medical advice. Discuss your individual history with a qualified provider.